Drugs / ALVAC(2)
last change Jun 2010 re-read 2 minutes ago

ALVAC(2)

Vaccine

Developed for
melanoma
Investigated by
Sanofi Pasteur, a Sanofi Company

Trials 1 · a red edge is where a trial was stopped

20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00613509 Jun 2008 → Apr 2010 cancer, melanoma Sanofi Pasteur, a Sanofi Company Terminated No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ALVAC(2) ClinicalTrials.gov intervention name — accepted as the source's own label NCT00613509
Modality Vaccine “multi-antigen therapeutic vaccineNCT00613509